ImmuRAID-CEA antibody fragment labeled with Technetium-99m data

At the meeting of the Society of Nuclear Medicine in Orlando, Fla., the Morris Plains, N.J., company presented several trials of the agent, as well as other products.

In a Phase II trial in 54 patients with diverse lung cancers, sensitivity was 90 percent, with 85 percent accuracy. Previously unsuspected sites were found in 24 patients. Cancer was confirmed in 11, not confirmed in two, and is as yet unresolved in 11. A Phase III trial is underway. ...